Nicoletta Colombo, MD, PhD, Istituto Europeo di Oncologia, Milan, Italy, discusses the final overall survival (OS) results from the Phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644) evaluating maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer. The combination of olaparib and bevacizumab provided a clinically meaningful improvement in overall survival for first-line homologous recombination deficient patients with and without a BRCA mutation, confirming olaparib and bevacizumab as a standard of care in this setting. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
